References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin [Internet]. 2013;63(1):11–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23335087
- Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet [Internet].2010;376(9742):687–697. Available from: http://linkinghub.elsevier.com/retrieve/pii/S014067361061121X
- Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol [Internet].2015;26(1):141–148. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25316259
- Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol [Internet]. 2006;24(18):2903–2909. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16782930
- Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol [Internet].2008;19(8):1450–1457. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18558665
- Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol [Internet]. 2008;26(9):1435–1442. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18349393
- Kang Y-K, Kang W-K, Shin D-B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–673.
- Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–1553.
- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol [Internet]. 2006;24(31):4991–4997. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17075117
- Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.
- Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd. J Clin Oncol [Internet]. 2014;32(31):3520–3526. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25287828
- Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol [Internet]. 2011;29(30):3968–3976. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.36.2236
- Lordick F, Kang Y-K, Chung H-C, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol [Internet]. 2013;14(6):490–499. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204513701025
- Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol [Internet]. 2013;14(6):481–489. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204513700962
- Hecht JR, Bang Y-J, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC- A randomized phase III trial. J Clin Oncol [Internet]. 2015;34(5):443–451. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26628478
- Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221.
- Ryu M-H, Baba E, Lee KH, et al. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol [Internet]. 2015;26(10):2097–2101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26216386
- Chuah B, Goh B-C, Lee S-C, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between caucasian and East Asian patients. Cancer Sci [Internet]. 2011;102(2):478–483. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21143703
- Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant tre. J Clin Oncol [Internet]. 2012;30(27):3353–3360. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22915656
- Mochizuki Y, Ohashi N, Kojima H, et al. CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702). Cancer Chemother Pharmacol [Internet]. 2013;72(3):629–635. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23881212
- Hamaguchi T, Shirao K, Ohtsu A, et al. A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the gastrointestinal oncology group of the Japan clinical oncology group (JCOG0109-DI trial). Gastric Cancer [Internet]. 2011;14(3):226–233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21503598
- Chon HJ, Rha SY, Park HS, et al. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Cancer Chemother Pharmacol [Internet]. 2011;68(4):991–999. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3180611&tool=pmcentrez&rendertype=abstract
- Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol [Internet]. 2013;71(2):481–488. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23192279
- Ando T, Hosokawa A, Kajiura S, et al. Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy. Gastric Cancer [Internet]. 2012;15(4):427–432. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22252156
- Shitara K, Yuki S, Tahahari D, et al. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Br J Cancer [Internet]. 2014;110(2):271–277. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3899763&tool=pmcentrez&rendertype=abstract
- Sasaki Y, Nishina T, Yasui H, et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci [Internet]. 2014;105(7):812–817. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24716542
- Zheng Y, Fang W, Mao C, et al. Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. Cancer Chemother Pharmacol [Internet]. 2014;74(3):503–509. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25038612
- Zhang X-D, Shu Y-Q, Liang J, et al. Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chin J Cancer Res. [Internet]. 2012;24(4):291–298. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3551331&tool=pmcentrez&rendertype=abstract
- Lin R, Fan N, Wu G, et al. A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer. J Chemother [Internet]. 2015;27(1):52–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24964957
- Sym SJ, Chang HM, Kang HJ, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother. Pharmacol. [Internet]. 2008;63(1):1–8. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-39149107799&partnerID=40&md5=3ac4b19629b2116fd538fd6c6c11106a
- Lv F, Liu X, Wang B, et al. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. Int J Clin Exp Pathol [Internet]. 2014;7(7):4274–4279. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4129044&tool=pmcentrez&rendertype=abstract
- Miranda MB, Hartmann JT, Al-Batran SE, et al. Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol [Internet]. 2014;140(5):829–837. Available from: //wos
- Zhang DS, Jin Y, Luo HY, et al. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study. Br J Cancer [Internet]. 2015;112(2):266–270. Available from: http://www.nature.com/doifinder/10.1038/bjc.2014.607
- Jeong J, Jeung H-C, Rha SY, et al. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol [Internet]. 2008;19(6):1135–1140. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18272910
- Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer [Internet].2011;47(15):2306–2314. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21742485
- Kang JH, Il LS, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol [Internet]. 2012;30(13):1513–1518. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22412140
- Ford HER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol [Internet]. 2014;15(1):78–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24332238
- Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria. J Clin Oncol [Internet]. 2013;31(35):4438–4444. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24190112
- Higuchi K, Tanabe S, Shimada K, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer [Internet]. 2014;50(8):1437–1445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24560487
- Nishikawa K, Fujitani K, Inagaki H, et al. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer [Internet]. 2015;51(7):808–816. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25797356
- Tanabe K, Fujii M, Nishikawa K, et al. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol [Internet]. 2015;26(9):1916–1922. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26109630
- Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England) [Internet].2014;383(9911):31–39. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24094768
- Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol [Internet].2014;15(11):1224–1235. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25240821
- Satoh T, Xu R-H, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol [Internet].2014;32(19):2039–2049. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24868024
- Ohtsu A, Ajani JA, Bai Y-X, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol [Internet]. 2013;31(31):3935–3943. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24043745
- Koizumi W, Kurihara M, Satoh A, et al. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res [Internet]. 25(2B):1257–1262. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15865075
- Koizumi W, Morita S, Sakata Y. A randomized phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). Jpn J Clin Oncol [Internet]. 2015;45(3):303–306. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4340275&tool=pmcentrez&rendertype=abstract
- Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res [Internet]. 2000;60(7):1878–1886. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10766175
- Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest [Internet]. 2000;105(8):R15–24. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=517491&tool=pmcentrez&rendertype=abstract
- Romiti A, Cox MC, Sarcina I, et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol [Internet]. 2013;72(1):13–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23475105
- He S, Shen J, Hong L, et al. Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol [Internet]. 2012;29(1):100–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21264547
- Romiti A, Onesti CE, Roberto M, et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol [Internet]. 2015;32(3):54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25638466
- Miger J, Holmqvist A, X-F S, et al. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol [Internet]. 2014;31(3):870. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3933740&tool=pmcentrez&rendertype=abstract
- Roberto M, Romiti A, Onesti CE, et al. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anticancer Drugs [Internet]. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26473528
- Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature [Internet]. 2014;513(7517):202–209. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4170219&tool=pmcentrez&rendertype=abstract
- Ryu M-H, Yoo C, Kim JG, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer [Internet]. 2015;51(4):482–488. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25661103
- Kang Y-K, Rha SY, Tassone P, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer [Internet]. 2014;111(4):660–666. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4134501&tool=pmcentrez&rendertype=abstract
- Shen Y-C, Li C-P, Yen C-J, et al. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. Oncology [Internet]. 2014;87(2):104–113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25011938
- Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol [Internet]. 2014;15(9):1007–1018. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24965569
- Han F-H, Li H-M, Zheng D-H, et al. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol [Internet]. 2010;36(12):1172–1179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20888167
- Van Cutsem E, De Haas S, Kang Y-K, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol [Internet]. 2012;30(17):2119–2127. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22565005
- Martin-Richard M, Gallego R, Pericay C, et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs [Internet]. 2013;31(6):1573–1579. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24077981
- Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer [Internet]. 2011;47(10):1511–1520. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21561763
- Bang Y-J, Kang Y-K, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs [Internet]. 2011;29(6):1449–1458. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3171673&tool=pmcentrez&rendertype=abstract
- Yi JH, Lee J, Park SH, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer [Internet]. 2012;106(9):1469–1474. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3341944&tool=pmcentrez&rendertype=abstract
- Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol [Internet]. 2010;28(11):1904–1910. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20231677
- Yoon DH, Ryu M-H, Park YS, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer [Internet]. 2012;106(6):1039–1044. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3304416&tool=pmcentrez&rendertype=abstract
- Lee SJ, Lee J, Lee J, et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs [Internet]. 2013;31(6):1580–1586. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24013904
- Ramanathan RK, McDonough SL, Kennecke HF, et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005). Cancer [Internet]. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25827820
- Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol [Internet]. 2011;22(6):1367–1373. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3493129&tool=pmcentrez&rendertype=abstract
- Schoennemann KR, Bjerregaard JK, Hansen TP, et al. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer [Internet]. 2011;14(3):219–225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21409520
- Tebbutt NC, Parry MM, Zannino D, et al. Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer [Internet]. 2013;108(4):771–774. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3590676&tool=pmcentrez&rendertype=abstract
- Satoh T, Lee KH, Rha SY, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer [Internet]. 2015;18(4):824–832. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4572054&tool=pmcentrez&rendertype=abstract
- Kang Y-K, Muro K, Ryu M-H, et al. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs [Internet]. 2014;32(2):355–361. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24337769
- Shah MA, Wainberg ZA, Catenacci DVT, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Plos One [Internet]. 2013;8(3):e54014. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3597709&tool=pmcentrez&rendertype=abstract
- Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol [Internet]. 2013;31(26):3219–3225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23918952
- Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. ASCO Annu Meet Proc [Internet]. 2014. Available from: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4003
- Tatematsu M, Tsukamoto T, Mizoshita T. Role of Helicobacter pylori in gastric carcinogenesis: the origin of gastric cancers and heterotopic proliferative glands in Mongolian gerbils. Helicobacter [Internet]. 2005;10(2):97–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15810939
- Murphy A, Kelly RJ. Immunotherapy in upper GI malignancies. Curr Treat Options Oncol [Internet]. 2015;16(5):20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25859830
- Sato Y, Kondo M, Kohashi S, et al. A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. J Immunother [Internet]. 27(5):394–397. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15314548
- Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet (London, England) [Internet]. 1994;343(8906):1122–1126. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7910230
- Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother [Internet]. 2012;61(12):2251–2259. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3506195&tool=pmcentrez&rendertype=abstract
- Jeung H-C, Moon YW, Rha SY, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol [Internet].2008;19(3):520–526. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18029971
- Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol [Internet]. 2015;6(5):561–569. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4570917&tool=pmcentrez&rendertype=abstract
- Saito H, Kuroda H, Matsunaga T, et al. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol [Internet]. 2013;107(5):517–522. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23129549
- Tamura T, Ohira M, Tanaka H, et al. Programmed DEATH-1 LIGand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res [Internet]. 2015;35(10):5369–5376. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26408698
- Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol [Internet]. 2013;94(1):25–39. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3685017&tool=pmcentrez&rendertype=abstract
- Segal N, Antonia S, Brahmer J. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol [Internet]. 2014. Available from: https://scholar.google.it/scholar?q=Preliminary+data+from+a+multi-arm+expansion+study++of+MEDI4736%2C+an+anti-PD-L1+antibody.&btnG=&hl=it≈sdt=0%2C5#0
- Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016. May 3. pii: S1470-2045(16)00175-3. doi:10.1016/1470-2045(16)00175-3. [Epub ahead of print].
- De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol [Internet]. 2013;2045(13):1–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24314615
- Paoletti X, Oba K, Bang Y-J, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst [Internet]. 2013;105(21):1667–1670. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24108811
- André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–431. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24913374